by Peter Ciszewski | Aug 14, 2018
Ron Cooper, President and CEO of Albireo, discusses drug development at Albireo, which has a clinical trial in progressive familial intrahepatic cholestasis (PFIC), a rare genetic condition that affects the liver. PFIC is estimated to affect between one in...
by Peter Ciszewski | Aug 13, 2018
Strongbridge Biopharma’s pivotal phase 3 SONICS study evaluating levoketoconazole (Recorlev) for the treatment of endogenous Cushing’s syndrome achieved statistical significance of its pre-specified primary endpoint. According to the company, 30% of patients...
by Peter Ciszewski | Aug 13, 2018
Editor’s Note: This interview was conducted at #BIO2018. Please pardon the background noise. Barry Greene, President of Alnylam, joined the company in 2003 and has more than 25 years of experience in healthcare, pharmaceutical, and biotechnology...
by Peter Ciszewski | Aug 12, 2018
Gail Cawkwell, MD, PhD, Senior Vice President, Medical Affairs at Intercept, provides an overview of the company. Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral...
by Peter Ciszewski | Aug 11, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals discusses his company’s growth over the past few years and provided an overview of Lenabasum, a novel, oral...
